```markdown
---
title: "Synchron Closes $275M Series E to Accelerate Stentrode BCI Commercialization"
date: 2026-06-29
category: Funding
excerpt: "Synchron raises $275M Series E to expand Stentrode BCI trials and push toward FDA approval for paralysis patients."
sponsored: false
---
Synchron, the endovascular brain-computer interface company, announced today the close of a $275 million Series E funding round led by General Atlantic, with participation from Khosla Ventures, ARCH Venture Partners, and strategic investor Medtronic. The raise brings Synchron's total funding to over $575 million and represents one of the largest single financing rounds in the commercial BCI sector to date.
The capital will be deployed across three primary areas: expanding the company's ongoing COMMAND pivotal trial in the United States and Australia, scaling its manufacturing facility in Brooklyn, and building out the clinical support infrastructure required for a potential FDA premarket approval submission, which the company is targeting for late 2027.
Where Synchron Stands Today
Synchron's Stentrode device distinguishes itself from competing BCI platforms by avoiding open-brain surgery. The device is delivered through the jugular vein and positioned in a blood vessel adjacent to the motor cortex, where it records neural signals that can be decoded to control computers, tablets, and communication software. The approach has so far been implanted in over 30 patients across multiple clinical sites, with the COMMAND trial designed to enroll 100 participants with amyotrophic lateral sclerosis and other severe motor impairments.
Early COMMAND data presented at the American Academy of Neurology annual meeting in May indicated that participants maintained stable signal quality at 18 months post-implant, a meaningful benchmark in an industry that has historically struggled with long-term electrode performance. Synchron CEO Tom Oxley noted in a statement that the new funding will help the company transition from a research-stage organization to one capable of supporting a commercial patient population.
What This Round Signals for the Industry
The Series E arrives at a moment of intensifying capital activity across the neurotech sector. Rival companies including Neuralink, Precision Neuroscience, and Paradromics are all advancing implantable BCI programs with varying surgical approaches and target applications. Medtronic's participation in this round is particularly notable given the device giant's existing dominance in deep brain stimulation, suggesting that established medtech players are moving to secure positions in next-generation neural interface platforms before regulatory pathways become clearly defined.
Analysts following the space will be watching whether this level of late-stage private investment accelerates FDA engagement on BCI-specific guidance documents, a policy development that multiple companies have openly lobbied for throughout 2025 and 2026. For now, Synchron's expanded war chest positions it as the best-capitalized pure-play BCI company currently in pivotal trials.